Literature DB >> 29079595

Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study.

Sebastian Botzenhardt1, Mariagrazia Felisi2, Donato Bonifazi2, Giovanni C Del Vecchio3, Maria C Putti4, Antonis Kattamis5, Adriana Ceci2,6, Ian C K Wong7,8, Antje Neubert9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29079595      PMCID： PMC5777195          DOI： 10.3324/haematol.2017.176065

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.

Authors:  Moshen S ElAlfy; Moshen El Alfy; Teny Tjitra Sari; Chan Lee Lee; Fernando Tricta; Amal El-Beshlawy
Journal:  J Pediatr Hematol Oncol       Date:  2010-11       Impact factor: 1.289

2.  Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.

Authors:  M B Agarwal; S S Gupte; C Viswanathan; D Vasandani; J Ramanathan; N Desai; R R Puniyani; A T Chhablani
Journal:  Br J Haematol       Date:  1992-10       Impact factor: 6.998

3.  A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

Authors:  M A Tanner; R Galanello; C Dessi; G C Smith; M A Westwood; A Agus; M Roughton; R Assomull; S V Nair; J M Walker; D J Pennell
Journal:  Circulation       Date:  2007-03-19       Impact factor: 29.690

4.  Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.

Authors:  Caterina Borgna-Pignatti; Maria Domenica Cappellini; Piero De Stefano; Giovanni Carlo Del Vecchio; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Maria Antonietta Romeo; Huaqing Zhao; Avital Cnaan
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

Review 5.  Safety profiles of iron chelators in young patients with haemoglobinopathies.

Authors:  Sebastian Botzenhardt; Niya Li; Esther W Chan; Chor Wing Sing; Ian C K Wong; Antje Neubert
Journal:  Eur J Haematol       Date:  2017-01-19       Impact factor: 2.997

6.  Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.

Authors:  Amal M El-Beshlawy; Mohsen S El-Alfy; Teny T Sari; Lee L Chan; Fernando Tricta
Journal:  Eur J Haematol       Date:  2014-01-30       Impact factor: 2.997

7.  The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.

Authors:  Adriana Ceci; Paola Baiardi; Mariagrazia Felisi; Maria Domenica Cappellini; Vittorio Carnelli; Vincenzo De Sanctis; Renzo Galanello; Aurelio Maggio; Giuseppe Masera; Antonio Piga; Francesco Schettini; Ippazio Stefàno; Fernando Tricta
Journal:  Br J Haematol       Date:  2002-07       Impact factor: 6.998

8.  Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.

Authors:  Alan R Cohen; Renzo Galanello; Antonio Piga; Vincenzo De Sanctis; Fernando Tricta
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

9.  Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.

Authors:  Sebastian Botzenhardt; Chor W Sing; Ian C K Wong; Godfrey Chi-Fung Chan; Lisa Y L Wong; Mariagrazia Felisi; Wolfgang Rascher; Adriana Ceci; Antje Neubert
Journal:  Curr Drug Saf       Date:  2016

10.  Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.

Authors:  Vip Viprakasit; Issarang Nuchprayoon; Ampaiwan Chuansumrit; Kitti Torcharus; Bunchoo Pongtanakul; Jiraporn Laothamatas; Somdet Srichairatanakool; Julaporn Pooliam; Siriwat Supajitkasem; Prapat Suriyaphol; Voravarn S Tanphaichitr; Soodsarkorn Tuchinda
Journal:  Am J Hematol       Date:  2013-03-05       Impact factor: 10.047
View more
  2 in total

1.  Predicting factors for liver iron overload at the first magnetic resonance in children with thalassaemia major.

Authors:  Maddalena Casale; Maria Marsella; Massimiliano Ammirabile; Anna Spasiano; Silvia Costantini; Patrizia Cinque; Paolo Ricchi; Aldo Filosa
Journal:  Blood Transfus       Date:  2018-06-26       Impact factor: 3.443

2.  Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

Authors:  Nancy F Olivieri; Amir Sabouhanian; Brenda L Gallie
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.